PMID- 36221383
OWN - NLM
STAT- MEDLINE
DCOM- 20221013
LR  - 20230103
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 101
IP  - 40
DP  - 2022 Oct 7
TI  - Bioinformatics analysis of the clinical significance of HLA class II in breast 
      cancer.
PG  - e31071
LID - 10.1097/MD.0000000000031071 [doi]
LID - e31071
AB  - Human leukocyte antigen (HLA) class II plays critical roles in antigen 
      presentation and the initiation of immune responses. However, the correlation 
      between the HLA class II gene expression level and the survival of patients with 
      breast cancer is still under investigation. We analyzed microarray and RNA-Seq 
      data of breast cancer from the cancer genome atlas (TCGA), genotype-tissue 
      expression (GTEx) and Oncomine databases by using bioinformatics tools. The 
      expression of the HLA-DQA1, HLA-DQA2, and HLA-DQB2 genes was significantly 
      upregulated in breast cancer. Higher expression levels of HLA class II genes in 
      breast cancer, especially HLA-DOB and HLA-DQB2, were significantly associated 
      with better overall survival. Furthermore, the expression of HLA class II genes 
      was more closely associated with survival in breast cancer than in other cancer 
      types. CD48 coexpressed with both HLA-DOB and HLA-DQB2 was also positively 
      associated with the overall survival of breast cancer patients. The results 
      indicated that HLA class II and CD48 may enhance antitumor immunity, and their 
      expression patterns may serve as potential prognostic biomarkers and therapeutic 
      targets in breast cancer.
CI  - Copyright (c) 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Wu, Guihua
AU  - Wu G
AD  - Finance Section, Yuebei People's Hospital, Shantou University, Shaoguan, China.
FAU - Xiao, Gaofang
AU  - Xiao G
AD  - Department of Pathology, Yuebei People's Hospital, Shantou University, Shaoguan, 
      China.
FAU - Yan, Yuhang
AU  - Yan Y
AD  - Breast Surgery, The Sixth Affiliated Hospital of Guangzhou Medical University, 
      Qingyuan People's Hospital, Qingyuan, China.
FAU - Guo, Chengwei
AU  - Guo C
AD  - Department of Radiology, 82 Group Hospital of PLA, Baoding, China.
FAU - Hu, Ningdong
AU  - Hu N
AD  - Thoracic surgery, The Sixth Affiliated Hospital of Guangzhou Medical University, 
      Qingyuan People's Hospital, Qingyuan, China.
FAU - Shen, Sandi
AU  - Shen S
AD  - Breast Surgery, The Sixth Affiliated Hospital of Guangzhou Medical University, 
      Qingyuan People's Hospital, Qingyuan, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Biomarkers)
SB  - IM
MH  - Biomarkers
MH  - Breast
MH  - *Breast Neoplasms/genetics
MH  - Computational Biology
MH  - Female
MH  - Humans
PMC - PMC9543021
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2022/10/13 06:00
MHDA- 2022/10/14 06:00
PMCR- 2022/10/07
CRDT- 2022/10/12 01:52
PHST- 2022/10/12 01:52 [entrez]
PHST- 2022/10/13 06:00 [pubmed]
PHST- 2022/10/14 06:00 [medline]
PHST- 2022/10/07 00:00 [pmc-release]
AID - 00005792-202210070-00060 [pii]
AID - 10.1097/MD.0000000000031071 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2022 Oct 7;101(40):e31071. doi: 
      10.1097/MD.0000000000031071.